Merck Sharp + Dohme Corp.

Lexicon Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Li Dong

Anandan Palani

Robert G Aslanian

Xianhai Huang

Kevin D McCormick

Christopher W Boyce

Ashwin Umesh Rao

Ning Shao

Younong Yu

Salem Fevrier

Jie Wu

Hongjun Zhang

Michael Berlin

Phieng Siliphaivanh

Pauline C Ting

Purakkattle J Biju

Rongze Kuang

Jianhua Chao

Manuel De Lera Ruiz

Junying Zheng

Walter Won

Dong Xiao

Joey Lee Methot

Robert D Mazzola, Jr

Cynthia Anne Fink

Wei Zhou

Qin Jiang

Jun Qin

Elizabeth Helen Kelley

Rachel Nicola MacCoss

Pawan Dhondi

Jiancheng Wang

Jolicia Polivina Gauuan

Andrew J Leyhane

John E Macor

Brian Alexander McKittrick

Jason D Brubaker

Joanne J Bronson

Ying Huang

Kenneth Gordon Carson

Yulian Zhang

Carolyn Diane Dzierba

Joshua Close

Yingzhi Bi

Michael Alan Green

Joon Jung

Giovanni Cianchetta

Xiao Chen

John W Butcher

John P Caldwell

Joseph Barbosa

Haiqun Tang

Henry M Vaccaro

Michelle Martinez

Scott Peterson

Sylvia Joanna Degrado

William Colby Brown

David Kimball

Soojin Kwon

Greg Zipp

G Gregory Zipp

Youngong Yu

Cynthia Ann Fink

Purakkattle Johny Biju

Scott L Peterson

Michael Green

Robert George Aslanian

Kevin D Mccormic

Joe Lee Method

Joshua T Close

Pawan K Dhondi

Brian A Mckittrick

Kevin D Mccormick

Rachel N Maccoss

Robert D Mazzola

Joon O Jung

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.

Multicyclic compounds and methods of their use

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.

Modulators of G protein-coupled receptor 88

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

Growing community of inventors

Lawrenceville, NJ, United States of America

Li Dong